Exercise-Induced Alterations in Adipose Tissue Cellular Composition

Overview

About this study

The purpose of this study is to determine how exercise-induced alterations in adipose tissue cellular composition and endocrine signaling may contribute to the beneficial adaptations to exercise in aging and obesity.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

Study group 1: Older adults with obesity

  • Participant must have a BMI between 30 and 40
  • Participant must be aged between 65 and 85

Study group 2: Older adults without obesity

  • Participant must have a BMI between 18.5 and 28
  • Participant must be aged between 65 and 85

Study group 3: Young adults with obesity

  • Participant must have a BMI between 30 and 40
  • Participant must be aged between 18 and 35

Study group 4: Young adults without obesity

  • Participant must have a BMI between 18.5 and 28
  • Participant must be aged between 18 and 35
  • Participant must use the Mayo Clinic patient online portal.
  • Participant must be able to understand English without the need of an interpreter.
  • Participant must be willing to be contacted for research
  • Participant must be willing and capable to provide consent.
  • Participants shall be generally healthy as deemed acceptable by the principal investigator
  • Men and women will be participant in this study

Exclusion Criteria:

  • Pparticipation in ≥ 30 minutes of structured physical activity ≥ 2 days per week
  • Smoking/tobacco use
  • Alcohol/substance abuse
  • Pregnancy and breastfeeding
  • Anemia (female subjects hemoglobin of <11 g/dl and male subjects hemoglobin <12 g/dl)
  • Abnormal renal function (serum creatinine > 1.5mg/dl)
  • Ddiagnosed diabetes or fasting plasma glucose ≥126
  • Blood clotting disorders or oral warfarin group medications
  • Coronary artery disease or history of unstable macrovascular disease
  • Uncontrolled thyroid disease (TSH undetectable or ≥6 mIU/L)
  • Abnormal liver function (AST>144IU/L or ALT>165IU/L)
  • INR >2.0
  • Use of medications known to influence the main outcomes of the study
  • Orthopedic problems that may be aggravated by exercise
  • Participants may also be excluded based on any known medical condition/s that in the judgment of the investigator might interfere with the completion of the protocol or medication/s that the investigator believes is a  contraindication to the subject’s participation.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/17/24. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hawley Kunz, Ph.D.

Open for enrollment

Contact information:

Rachel Passehl

(507) 255-8112

Passehl.Rachel@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20555803

Mayo Clinic Footer